

ONLINE FILING

Date: 1st February, 2022

<p>The Secretary National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051</p>	<p>The Secretary, BSE Ltd Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001</p>
--	--

Sub: Outcome of Board Meeting held on 01st February, 2022

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we wish to inform you that the Board of Directors of Artemis Medicare Services Limited ("the Company" or "Artemis Hospital") at its meeting held today, inter alia, considered and approved the following:

1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December, 2021 prepared in terms of Regulation 33 of the Listing Regulations along with the Limited Review Reports thereon issued by the Statutory Auditors of the Company. The said Unaudited Financial Results are enclosed herewith;
2. Arrangement with PolyClinique De L'Ouest Ltee, Republic of Mauritius for the Operation and Management of two Hospitals – namely, St Helene Clinique and Coromandel Cancer Hospitals (Currently under construction), the details whereof is provided below:

Sr. No.	Hospital Name	Bed Capacity	Expected Launch Time
1.	St Helene Clinique	78	January, 2023
2.	Coromandel Cancer Hospital	121	July, 2023

Currently Artemis Hospital is running 5 Cardiac centres under the Joint Venture with Philips Medical System Nederland BV and one Obstetrics and Gynecology centre under Brand "Daffodils by Artemis".

The meeting of the Board of Directors commenced at 03:30 PM and concluded at 5:30 PM

Submitted for your information & records.

For Artemis Medicare Services Limited

Shilpa Budhia

Shilpa Budhia
(Company Secretary & Compliance Officer)
Encl. A/a





Independent Auditor's Review Report on quarterly and year to date unaudited consolidated financial results of Artemis Medicare Services Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Artemis Medicare Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Artemis Medicare Services Limited** ('the Parent') and its subsidiary (the Parent and its subsidiary together referred to as 'the Group') for the quarter ended December 31, 2021, and year to date from April 1, 2021, to December 31, 2021 (hereinafter referred to as the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing regulation").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with circular no. CIR/CFD/CMD/1/44/2019 dated March 29, 2019, issued by the SEBI under Regulations 33(8) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2018 as amended, to the extent applicable.

4. The Statement includes the results of the Parent and the following subsidiary:
 - a. **Artemis Cardiac Care Private Limited**
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India has not disclosed the information required to be disclosed



in terms of Regulation 33 of Listing Regulations (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

6. We did not review the interim financial results of the subsidiary i.e. Artemis Cardiac Care Private Limited included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs. 1819.35 lakhs as of December 31, 2021, and total revenues of Rs. 226.64 lakhs and Rs. 680.58 lakhs, net loss after tax of Rs. (37.12) lakhs and Rs. (106.33) lakhs and total comprehensive income of Rs. 0.16 lakhs and Rs. 0.48 lakhs, for the quarter ended December 31, 2021, and for the period from April 1, 2021, to December 31, 2021, respectively, and cash flows (net) of Rs. (165.91) lakhs for the period from April 1, 2021, to December 31, 2021, as considered in the consolidated unaudited financial results. These interim financial statements and other financial information have been reviewed by another firm of Chartered accountants whose reports have been furnished to us by the Management and our conclusion on the statement in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the report of such other firm of chartered accountants and the procedures performed by us as stated in paragraph 3 above.
7. The Statement includes comparative figures for the corresponding quarter and half year ended December 31, 2020, reviewed by the predecessor auditors of the Parent, where they had expressed an unmodified conclusion vide their report dated February 4, 2021, on such financial results.

The Statement also includes figures for the year ended March 31, 2021, audited by the predecessor auditor of the Parent, where they had expressed an unmodified opinion on such financial statements vide their report dated May 10, 2021.

Our conclusion on the Statement is not modified in respect of these matters.

For T R Chadha & Co LLP
Chartered Accountants
(Firm Registration No -006711N/ N500028)

NEENA
GOEL

Digitally signed by
NEENA GOEL
Date: 2022.02.01
17:08:15 +05'30'

Neena Goel
(Partner)
Membership No. 057986

Place of Signature: Delhi
Dated: February 1, 2022
UDIN: 22057986AAAAAZ9246

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Website: www.artemishospitals.com


CIN: L85110DL2004PLC126414

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in Lacs)

S No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Income						
	(a) Revenue from Operations	14,404.69	13,903.73	12,418.69	40,536.92	27,924.45	40,840.34
	(b) Other Income	100.06	85.55	68.47	266.08	214.21	353.83
	Total Income	14,504.75	13,989.28	12,487.16	40,803.00	28,138.66	41,194.17
2.	Expenses						
	(a) Operative Expenses	8,775.40	8,467.60	7,667.12	24,832.89	17,614.79	25,482.08
	(b) Purchases of Stock in Trade	1.56	1.22	-	9.48	23.08	29.71
	(c) Changes in inventories of Stock in Trade	3.34	3.68	7.00	9.51	44.01	45.64
	(d) Employee Benefits Expense	2,629.21	2,459.31	2,186.73	7,540.11	6,210.19	8,399.01
	(e) Finance Costs	319.08	269.14	307.45	826.72	1,033.75	1,292.53
	(f) Depreciation and Amortization Expense	558.15	514.86	534.36	1,579.95	1,640.83	2,151.38
	(g) Other Expenses	1,224.30	1,003.46	952.24	3,105.27	2,536.00	3,364.09
	Total Expenses	13,511.04	12,719.27	11,654.90	37,903.93	29,102.65	40,764.44
3.	Profit/(Loss) before exceptional items and tax (1-2)	993.71	1,270.01	832.26	2,899.07	(963.99)	429.73
4.	Exceptional Items (Refer Note 8)	-	-	-	-	-	323.29
5.	Profit/(Loss) before tax (3+4)	993.71	1,270.01	832.26	2,899.07	(963.99)	753.02
6.	Tax Expense:						
	(a) Current Tax	329.31	429.24	-	1,050.17	-	670.51
	(b) Earlier Year Tax	-	-	-	-	-	94.14
	(c) Deferred Tax Charge / (Credit)	28.05	31.37	307.03	29.39	(314.83)	(627.63)
	Total Tax Expense	357.36	460.61	307.03	1,079.56	(314.83)	137.02
7.	Net Profit/(Loss) after tax for the period/ year (5-6)	636.35	809.40	525.23	1,819.51	(649.16)	616.00
8.	Other comprehensive income/(loss) for the period/year						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined employee benefit plans	(1.32)	(5.04)	(2.78)	(3.95)	(8.32)	9.62
	(b) Income Tax relating to items that will not be reclassified to profit or loss	0.48	1.77	0.97	1.43	2.91	(3.30)
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	13.55	13.56	10.17	40.66	30.50	40.66
	Net Other comprehensive income/(loss) for the period/year	12.71	10.29	8.36	38.14	25.09	46.98
9.	Total comprehensive income/(loss) for the period/ year (7+8)	649.06	819.69	533.59	1,857.65	(624.07)	662.98
10.	Profit/(Loss) for the period attributable to :						
	Shareholders of the Company	649.34	818.91	533.72	1,856.73	(621.39)	648.59
	Non-Controlling Interest	(12.99)	(9.51)	(8.49)	(37.22)	(27.77)	(32.59)
11.	Total Comprehensive Income / (Loss) for the period attributable to :						
	Shareholders of the Company	661.99	829.14	542.08	1,894.70	(596.30)	695.33
	Non-Controlling Interest	(12.94)	(9.45)	(8.49)	(37.05)	(27.77)	(32.35)
12.	Paid up Equity Share Capital (Face value Re. 1/- each) (Refer Note 6)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
13.	Other Equity Excluding Revaluation Reserves	-	-	-	-	-	24,056.65
14.	Earning per Equity Share (Face value Re. 1/- each) (Refer Note 6)						
	(a) Basic	0.49*	0.62*	0.40*	1.40*	-0.47*	0.49
	(b) Diluted	0.47*	0.59*	0.40*	1.34*	-0.47*	0.49

* Not annualised



Omber Kaumar

Notes:-

- The above consolidated unaudited financial results for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on February 1, 2022. The results for the quarter and nine months ended 31 December 2021 presented were subjected to a "Limited review" by the Statutory Auditors of the Company. The statutory auditors have expressed unmodified conclusion on the aforesaid results.
- The consolidated unaudited financial results includes the results of the Company and one subsidiary. The Company together with its subsidiary is herein referred to as the Group.
- The above consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
- The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, carrying amounts & recoverability of receivables and other current assets, assessment of liquidity and going concern assumption, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter and nine months ended 31st December, 2021.
- India's Code on Social Security, 2020, which aims to consolidate, codify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Code may impact the contributions by the Group towards provident fund, gratuity and ESIC. The Group will assess the impact of this Code and the rules thereunder when they come into effect and will record any related impact, if any, in the period the Code becomes effective.
- The Board of Directors of Artemis Medicare Services Limited ('Group') in its meeting held on August 5, 2021, approved a proposal for sub-division of the face value of the equity shares of the Company from Rs. 10 per equity share to Re. 1 per equity share i.e. 1 equity share to be split into 10 equity shares. Subsequent to the approval of the above proposal by the shareholders of the Company, the record date was fixed as September 24, 2021 and thereafter the sub-division became effective. Accordingly, the basic and diluted earnings per equity share (EPS) have been computed for all the periods presented in the Consolidated Financial Results of the Group on the basis of new number of equity shares in accordance with Ind AS 33 - Earnings per shares.

7. Segment Reporting at Consolidated levelBusiness segment

The Group's operation predominantly comprise of only one business segment of Healthcare Services.

Geographical information

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations					
	Quarter ended			Nine Months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
India	11,813.76	12,250.20	9,808.76	34,408.22	24,429.78	34,685.64
Outside India	2,590.93	1,653.53	2,609.93	6,128.70	3,494.67	6,154.70
Total	14,404.69	13,903.73	12,418.69	40,536.92	27,924.45	40,840.34

Region	Carrying amount of Non-Current Assets					
	Quarter ended			Nine Months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
India	54,822.80	52,734.64	47,867.75	54,822.80	47,867.75	48,783.32
Outside India	-	-	-	-	-	-
Total	54,822.80	52,734.64	47,867.75	54,822.80	47,867.75	48,783.32

8. For the previous year ended March 31, 2021, exceptional item consist of reversal of old disputed liability of Rs. 323.29 lacs carried forward from Artemis Global Life Sciences Limited (AGLSL) (the erstwhile ultimate parent company of Artemis Medicare Services Limited) prior to the merger which was under Arbitration. The Management has been advised by an independent legal expert that since the Arbitration proceedings are not being carried out for last many years, this amount is now no longer payable. Accordingly, the same has been written back by the Holding Company.

9. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification/disclosures.



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Place : Gurugram
Dated : February 1, 2022



Independent Auditor's Review Report on quarterly and year to date unaudited standalone financial results of Artemis Medicare Services Limited pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Artemis Medicare Services Limited**

1. We have reviewed the Statement of Unaudited Standalone Financial Results of **Artemis Medicare Services Limited** ('the Company') for the quarter ended December 31, 2021, and year to date from April 1, 2021, to December 31, 2021 (hereinafter referred to as "Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to date ("Listing regulation"), which has been initialed by us for identification purposes.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance so as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in all material respects in accordance with applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Listing Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

5. The Statement includes comparative figures for the corresponding quarter and nine months ended December 31, 2020, reviewed by the predecessor auditors of the Company, where they had expressed an unmodified conclusion vide their report dated February 4, 2021, on such financial results.



The Statement also includes figures for the year ended March 31, 2021, audited by the predecessor auditor of the Company, where they had expressed an unmodified opinion on such financial statements vide their report dated May 10, 2021.

Our conclusion on the Statement is not modified in respect of these matters.

For T R Chadha & Co LLP
Chartered Accountants
(Firm Registration No -006711N/ N500028)

NEENA
GOEL

Digitally signed
by NEENA GOEL
Date: 2022.02.01
16:50:45 +05'30'

Neena Goel
(Partner)
Membership No. 057986

Place of Signature: Delhi
Dated: February 1, 2022
UDIN: 22057986AAAAAY4993

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124 4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Website: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

S No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Income						
	(a) Revenue from Operations	14,178.63	13,631.96	12,227.01	39,858.86	27,482.98	40,206.37
	(b) Other Income	99.01	85.43	68.58	264.80	214.81	354.56
	Total Income	14,277.64	13,717.39	12,295.59	40,123.66	27,697.79	40,560.93
2.	Expenses						
	(a) Operative Expenses	8,630.34	8,301.63	7,546.62	24,411.30	17,322.38	25,088.03
	(b) Purchases of Stock in Trade	1.56	1.22	-	9.48	23.08	29.71
	(c) Changes in inventories of Stock in Trade	3.34	3.68	7.00	9.51	44.01	45.64
	(d) Employee Benefits Expense	2,576.87	2,411.77	2,149.89	7,394.09	6,104.43	8,248.65
	(e) Finance Costs	299.77	248.02	290.90	766.57	988.31	1,226.89
	(f) Depreciation and Amortization Expense	530.68	487.98	510.35	1,499.24	1,580.90	2,065.22
	(g) Other Expenses	1,189.95	955.92	917.01	3,002.43	2,483.86	3,289.49
	Total Expenses	13,232.51	12,410.22	11,421.77	37,092.62	28,546.97	39,993.63
3.	Profit/(Loss) before exceptional items and tax (1-2)	1,045.13	1,307.17	873.82	3,031.04	(849.18)	567.30
4.	Exceptional Items (Refer Note 4)	-	-	-	-	-	323.29
5.	Profit/(Loss) before tax (3+4)	1,045.13	1,307.17	873.82	3,031.04	(849.18)	890.59
6.	Tax Expense:						
	(a) Current Tax	329.31	429.24	-	1,050.17	-	670.51
	(b) Earlier Year Tax	-	-	-	-	-	94.14
	(c) Deferred Tax Charge / (Credit)	42.45	41.47	324.42	55.33	(279.05)	(582.77)
	Total Tax Expense	371.76	470.71	324.42	1,105.50	(279.05)	181.88
7.	Net Profit/(Loss) after tax for the period/ year (5-6)	673.37	836.46	549.40	1,925.54	(570.13)	708.71
8.	Other comprehensive income/(loss) for the period/year						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined employee benefit plans	(1.54)	(5.25)	(2.78)	(4.61)	(8.32)	8.70
	(b) Income Tax relating to items that will not be reclassified to profit or loss	0.54	1.83	0.97	1.61	2.91	(3.04)
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	13.55	13.56	10.17	40.66	30.50	40.66
	Net Other comprehensive income/(loss) for the period/year	12.55	10.14	8.36	37.66	25.09	46.32
9.	Total comprehensive income/(loss) for the period/ year (7+8)	685.92	846.60	557.76	1,963.20	(545.04)	755.03
10.	Paid up Equity Share Capital (Face value Re. 1/- each) (Refer Note 5)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
11.	Other Equity Excluding Revaluation Reserves	-	-	-	-	-	24,199.27
12.	Earning per Equity Share (Face value Re. 1/- each) (Refer Note 5)						
	(a) Basic	0.51*	0.63*	0.42*	1.45*	-0.43*	0.54
	(b) Diluted	0.48*	0.60*	0.42*	1.39*	-0.43*	0.54

* Not annualised



Omlee Kaumar

Notes:-

- The above standalone unaudited financial results for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on February 1, 2022. The results for the quarter and nine months ended 31 December 2021 presented were subjected to a "Limited review" by the Statutory Auditors of the Company. The statutory auditors have expressed unmodified conclusion on the aforesaid results.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
- The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, carrying amounts & recoverability of receivables and other current assets, assessment of liquidity and going concern assumption, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter and nine months ended 31st December, 2021.
- For the previous year ended March 31, 2021, exceptional item consist of reversal of old disputed liability of Rs. 323.29 lacs carried forward from Artemis Global Life Sciences Limited (AGLSL) (the erstwhile ultimate parent company of Artemis Medicare Services Limited) prior to the merger which was under Arbitration. The Management has been advised by an independent legal expert that since the Arbitration proceedings are not being carried out for last many years, this amount is now no longer payable. Accordingly, the same has been written back by the Company.
- The Board of Directors of Artemis Medicare Services Limited ('Company') in its meeting held on August 5, 2021, approved a proposal for sub-division of the face value of the equity shares of the Company from Rs. 10 per equity share to Re. 1 per equity share i.e. 1 equity share to be split into 10 equity shares. Subsequent to the approval of the above proposal by the shareholders of the Company, the record date was fixed as September 24, 2021 and thereafter the sub-division became effective. Accordingly, the basic and diluted earnings per equity share (EPS) have been computed for all the periods presented in the Standalone Financial Results of the Company on the basis of new number of equity shares in accordance with Ind AS 33 - Earnings per shares.

6. Segment Reporting:

Business segment

The Company's operation predominantly comprise of only one business segment of Healthcare Services.

Geographical information

Geographical information analyses the Company's revenue by the country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations					
	Quarter ended			Nine Months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
India	11,587.70	11,978.43	9,617.08	33,730.16	23,988.31	34,051.67
Outside India	2,590.93	1,653.53	2,609.93	6,128.70	3,494.67	6,154.70
Total	14,178.63	13,631.96	12,227.01	39,858.86	27,482.98	40,206.37

Region	Carrying amount of Non-Current Assets					
	Quarter ended			Nine Months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
India	53,669.08	51,599.79	46,715.05	53,669.08	46,715.05	47,617.71
Outside India	-	-	-	-	-	-
Total	53,669.08	51,599.79	46,715.05	53,669.08	46,715.05	47,617.71

7. India's Code on Social Security, 2020, which aims to consolidate, codify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Code may impact the contributions by the company towards provident fund, gratuity and ESIC. The Company will assess the impact of this Code and the rules thereunder when they come into effect and will record any related impact, if any, in the period the Code becomes effective.

8. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification/disclosures.



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Place : Gurugram
Dated : February 1, 2022